Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fennec PharmaceuticalsFENC +0.97%54 Days Sales Outstanding is 107.28 as of Jun. 2026, which is 10% below its 10-year median of 119.22. GuruFocus rates FENC with a GF Score™ of 54/100 and a GF Value™ of $10.77 (Fairly Valued). The stock has 1 warning sign investors should review. Among 835 Biotechnology companies, Fennec Pharmaceuticals ranks worse than 78.56% on this metric.
Fennec Pharmaceuticals (NAS:FENC) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Fennec Pharmaceuticals Days Sales Outstanding Related Terms
Fennec Pharmaceuticals Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Fennec Pharmaceuticals's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fennec Pharmaceuticals Days Sales Outstanding Chart
FENC vs VRTX, REGN, RVMD: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Fennec Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fennec Pharmaceuticals Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Fennec Pharmaceuticals's Days Sales Outstanding falls into.
Fennec Pharmaceuticals Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 107.28 mean?
Fennec Pharmaceuticals (FENC) has a Days Sales Outstanding of 107.28 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Fennec Pharmaceuticals and its competitors. This is 10% below median its historical median of 119.22. Over the past decade, Fennec Pharmaceuticals' Days Sales Outstanding has ranged from 81.33 to 367.45. According to the industry distribution chart, Fennec Pharmaceuticals ranks #656 out of 835 companies in the Biotechnology industry, placing it in the top 78.6%.
Is Fennec Pharmaceuticals' Days Sales Outstanding too high?
Fennec Pharmaceuticals' current Days Sales Outstanding of 107.28 is 10% below median its 10-year median of 119.22. Over the past 10 years, this metric has ranged from a low of 81.33 to a high of 367.45. The Biotechnology industry median Days Sales Outstanding is 68.94. Fennec Pharmaceuticals' value of 107.28 is 55.6% above this industry median. Based on the distribution chart, Fennec Pharmaceuticals ranks #656 out of 835 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Fennec Pharmaceuticals has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fennec Pharmaceuticals' Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fennec Pharmaceuticals ranks #656 out of 835 companies for Days Sales Outstanding. This places Fennec Pharmaceuticals in the lower half of its industry. The industry median Days Sales Outstanding is 68.94. Fennec Pharmaceuticals' value of 107.28 is 55.6% above this benchmark. Historically, Fennec Pharmaceuticals' own Days Sales Outstanding has ranged from 81.33 to 367.45 over the past decade. While the company's 10-year median is 119.22 vs. the industry median of 68.94, Fennec Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 835 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fennec Pharmaceuticals's current Days Sales Outstanding of 107.28 is 55.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Fennec Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fennec Pharmaceuticals's current Days Sales Outstanding is 107.28, which is 10% below median its own 10-year median of 119.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fennec Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Fennec Pharmaceuticals (FENC) is currently considered Fairly Valued. The stock's GF Value™ is $10.77, compared to a current price of $11.38 — trading 5.7% above its estimated fair value. The current Days Sales Outstanding is 107.28, which is 10% below median its 10-year median of 119.22 and 55.6% above the Biotechnology industry median of 68.94. Fennec Pharmaceuticals' overall GF Score™ is 54/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Fennec Pharmaceuticals (FENC), the current Days Sales Outstanding is 107.28 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fennec Pharmaceuticals (FENC) Overvalued in 2026?
Based on GuruFocus' analysis, Fennec Pharmaceuticals stock appears to be overvalued.
The current stock price of $11.38 is trading 5.7% above its estimated GF Value™ of $10.77.
GuruFocus considers Fennec Pharmaceuticals to be Fairly Valued.
Key valuation signals for FENC:
Days Sales Outstanding: 107.28 (10% below median its 10-year median of 119.22)
GF Value™: $10.77 vs. price of $11.38 (5.7% above fair value)
Industry Position: 55.6% above the Biotechnology median (#656 of 835)
No single metric tells the full story. See the FENC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
54GF Score
Get the complete analysis for FENC
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FENC has been successfully added to your 
